Cancer Center Announces First Patient Has Received City ... - City of Hope

The Phase 1 clinical trial tests the safety of providing City of Hope-developed AOH1996 to people with reoccurring solid tumors. LOS ANGELES — City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient to receive its novel, promising cancer medicine AOH1996 is doing well.

Efficacy and safety of prostate radiotherapy in de novo metastatic ...

We conducted an open-label, randomised, controlled, phase 3 trial with a 2 × 2 factorial design (PEACE-1) at 77 hospitals across Europe. Eligible participants were male patients (aged ≥18 years) with de novo metastatic castration-sensitive prostate cancer confirmed by bone scan, CT, or MRI, and an Eastern Cooperative Oncology Group performance status of 0-1 (or 2 in the case of bone pain).

FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research

The FDA has approved the IND application for AS1986NS, an innovative drug designed to improve prostate cancer detection and treatment.1. This approval means the drug is now set to begin phase 1/2 clinical trials in early 2025. Developed by Antelope Surgical, AS1986NS combines a fluorescent marker with lutetium-175, a radioactive isotope, to ...

A new hope for men with metastatic prostate cancer

Montreal, April 11, 2024— The Research Institute of McGill University Health Centre (RI-MUHC) has enrolled this week the first patients to take part in an early-stage, multi-centre clinical trial of Actinium-225, a radioactive isotope used as a treatment for metastatic prostate cancer. The RI-MUHC is proud to be selected as the first site ...

Rethinking metastatic prostate cancer - Harvard Health

Just three to four decades ago, men with metastatic prostate cancer lived an average of 28 to 36 months. Today, the average life expectancy of someone with this diagnosis has increased to about five to six years, and experts are starting to view metastatic prostate cancer as potentially curable — a concept that would have been unimaginable a decade ago.

Early Phase Clinical Trial Program - Yale Cancer Center

The Early Phase Clinical Trial Infusion Center at Smilow Cancer Hospital opened in 2016 at 55 Park Street in New Haven, and is a dynamic hub of early phase trials. Attractive and state-of-the-art, the Center is at the heart of Yale Cancer Center's Early Phase Clinical Trial Program and is dedicated to the care and treatment of patients on ...

Prostate cancer: Three drug trials to watch

Mevrometostat blocks the effects of a protein called enhancer of zeste homolog 2 (EZH2). EZH2 is involved in prostate cancer cell growth. One of the targets involved in this process is a protein called H3K27Me3, which decreases cancer cell growth. "This trial is important because it's testing a novel pathway that's not really been fully ...

Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer

A decrease in prostate-specific antigen levels of 50% or more occurred in 14 of 19 (73.7%) patients with AR mut and 2 of 23 (8.7%) patients with AR wild type in phase 1 and in 24 of 45 (53.3%) patients with AR mut in phase 2.

City of Hope CAR T cell therapy for advanced prostate cancer ...

LOS ANGELES — A pioneering Phase 1 CAR T cell therapy trial for the treatment of glioblastoma at City of Hope, one of the largest cancer treatment and research organizations in the United States, demonstrates promising clinical activity against incurable brain tumors, according to research published today in Nature Medicine.

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate ...

That trial showed a 5-year failure-free survival of 84% (95% CI, 80 to 87) in each group, with an adjusted hazard ratio for biochemical or clinical failure of 1.00 (95% CI, 0.76 to 1.33; P=0.99 by ...